NuVasive’s Precice Bone Transport System receives US FDA & European approvals for use in segmental bone loss treatment

NuVasive, the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced it received 510(k) clearance from the US Food and Drug Administration (FDA) – as well as European CE mark approval – for use of its Precice Bone Transport System, the only all-internal system of its kind on the market indicated for use in segmental bone loss treatment in the tibia and femur resulting from trauma or infection.

The Precice Bone Transport System joins the NuVasive Specialized Orthopedics (NSO) family of advanced, magnetically adjustable limb-lengthening products which have collectively been used to treat thousands of patients. NSO is a division of NuVasive, focused on the design and innovation of disruptive orthopedic solutions, including its proprietary platform of magnetically adjustable implant systems.